Accéder au contenu
Merck

A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas.

Journal of the American Academy of Dermatology (2000-02-25)
R Bergman, H Azzam, E Sprecher, L Manov, M Munichor, R Friedman-Birnbaum, O Ben-Itzhak
RÉSUMÉ

The histopathologic differential diagnosis of Spitz nevus (SN) from malignant melanoma (MM) may be difficult. We attempted to elucidate the pattern of expression of a newly recognized melanocyte-specific melanosomal protein MART-1 in routinely processed specimens of SNs, MMs, and ordinary melanocytic nevi (MNs) and to see whether it can help to differentiate between them. Twenty SN, 22 MM, and 27 ordinary MN were immunostained with anti-MART-1 monoclonal antibody (clone A103). All SNs, MNs, and MMs demonstrated cytoplasmic staining for MART-1 in some of their tumor cells, of which 17 of 20 (85%) and 24 of 27 (89%) of SN and MN, respectively, demonstrated positive stainings in more than half of their tumor cells, as compared with only 10 of 22 (45%) of the MM (P <.05). The majority of lesions in all 3 types of tumors showed a homogeneous mode of staining, although MM tended to show a more heterogeneous pattern. A consistent pattern of stratification of staining with progressive descent into the dermis was not demonstrated in these tumors. MART-1 does not differentiate between SN, MM, and ordinary MN in a consistent pattern, but it may be used as a marker for these tumors.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
MART-1 (Melan A) (A103) Mouse Monoclonal Antibody
Sigma-Aldrich
MART-1 (Melan A) (M2-7C10) Mouse Monoclonal Antibody